Evidence map›Paper›PMID 20101429›Full record

ArticleClinical rheumatology2010

Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab.

Taner Babacan, Ahmet Mesut Onat, Yavuz Pehlivan, Gazi Comez, Metin Karakök

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Autoinflammatory diseases and the kidney.Immunologic research · 2023
    Review
  4. Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Taner BabacanDepartment of Internal Medicine, Gaziantep University, School of Medicine, Gaziantep, Turkey. mdbabacan@mynet.com
Ahmet Mesut Onat
Yavuz Pehlivan
Gazi Comez
Metin Karakök
Gaziantep University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult onset Still's Disease (ASD) is a systemic inflammatory disorder of unknown etiology characterized by chronic and fluctuant fever with accompanying rash, polyarthritis and involvement of multiple organs, especially lymphoid tissues. Although kidney involvement may appear in some cases of adult Still's disease, membranous glomerulonephyritis has not been described before. We herein report a 38-year-old man diagnosed with Still's disease with longstanding polyarthritis unresponsive to high-dose steroids and various immunosuppressive drugs for 5 years. He was referred to our clinic with bilateral pretibial edema on his legs. Urine examination revealed 10.5 g/day proteinuria with membranous glomerulonephritis and his renal biopsy came up with it. Infliximab was initiated, and his complaints were totally resolved also with a normal urine test in the following 3 months. To the best of our knowledge, this is the first report that clearly shows the efficacy of infliximab in a patient with refractory ASD with membranous glomerulonephyritis.

Indexed as

AdultAntibodies, MonoclonalAnti-Inflammatory AgentsGlomerulonephritis, MembranousHumansInfliximabMaleProteinuriaStill's Disease, Adult-OnsetAntibodies, MonoclonalAnti-Inflammatory AgentsInfliximab

Identifiers

PMID20101429
OpenAlexW2087509230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.